AccuImage qualifies for Over-the-Counter tradingThe OTC Bulletin Board has authorized AccuImage Diagnostics to begin trading its stock on the OTCBB under "AIDP" as of Oct. 23. The San Francisco-based imaging company counts year-to-date income
AccuImage qualifies for Over-the-Counter trading
The OTC Bulletin Board has authorized AccuImage Diagnostics to begin trading its stock on the OTCBB under "AIDP" as of Oct. 23. The San Francisco-based imaging company counts year-to-date income of $252,096 and revenue of $2.3 million and claims that its revenue has more than doubled over the same period in 1999. AccuImage develops three-dimensional visualization software, including products that enable 3-D Web-based PACS review, and digital image distribution and archiving technologies. The company is actively pursuing strategic alliances with equipment vendors and broadband providers.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.